Skip to main content
Clinical Trials/EUCTR2014-004176-35-Outside-EU/EEA
EUCTR2014-004176-35-Outside-EU/EEA
Active, not recruiting
Not Applicable

Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post Surgical Dental Pain: Study I

Pfizer0 sites316 target enrollmentJune 26, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post Surgical Dental Pain
Sponsor
Pfizer
Enrollment
316
Status
Active, not recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 26, 2015
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Pfizer

Eligibility Criteria

Inclusion Criteria

  • 1\. Males and females 16 years to 40 years of age (inclusive).
  • 2\. Outpatients who have moderate to severe post\-operative pain (confirmed by a Visual Analog Scale Pain Severity Rating Scale (VAS\-PSR) score of at least 50 mm on a 100\-mm VAS\-PSR) following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction.
  • 3\. Use of only the following pre\-operative medication(s)/anesthetic(s): topical benzocaine, a short\-acting parenteral (local) anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide.
  • 4\. Examined by the attending dentist or physician and medically cleared to participate in the study.
  • 5\. In general good health and have no contraindications to the study or rescue medication.
  • 6\. Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form.
  • 7\. Subjects (or the parent or legal guardian of subjects under the age of 18 years) are required to read, comprehend, and sign the informed consent. Subjects requiring a parent or legal guardian to sign the informed consent form will also be required to sign an assent.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 111
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • 1\.Presence or history of any significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorder determined by the Principal Investigator to place the subject at increased risk.
  • 2\.Use of a prescription or over\-the\-counter (OTC) drug with which administration of ibuprofen or any other non\-steroidal anti\-inflammatory drug (NSAID), acetaminophen (APAP), or hydrocodone is contraindicated (including: opioids, antipsychotics, antianxiety agents, or other central nervous system depressants \[including alcohol]).
  • 3\. Use of prescription or OTC antihistamines within 24 hours prior to taking study medication. (Note exceptions: loratadine \[Claritin], desloratadine \[Clarinex], cetirizine \[Zyrtec ], levocetirizine \[Xyzal], fexofendadine \[Allegra], and azelastine \[Intranasal, Astelin]).
  • 4\. Use of a bisphosphonate (e.g., pamidronate \[Aredia], risedronate \[Actonel], alendronate \[Fosamax], or ibandronate \[Boniva]) in the past 5\-years.
  • 5\. Acute localized dental alveolar infection at the time of surgery that could confound the post\-surgical evaluation.
  • 6\. Female subjects who are pregnant, lactating, of child\-bearing potential or post\-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine or intravaginal device \[IUD or NuvaRing ], diaphragm, condom, abstinence, or surgical sterility including partner’s vasectomy), or who test positive on a urine\-based pregnancy test.
  • 7\. Presence or history (within 2 years of enrollment) of gastrointestinal ulcer or gastrointestinal bleeding.
  • 8\. Presence or history (within 2 years of enrollment) of a bleeding disorder.
  • 9\. Presence or history of alcohol (3 or more alcoholic drinks per day on a regular basis) or substance abuse within 2 years of enrollment (note: one drink of alcohol is 1 oz. liquor, 6 oz. wine, or 12 oz. beer) or currently abusing other mood\-altering drugs (e.g., cannabis). Patients who are taking St. John’s Wort, or any other nutritional supplement known to have psychotropic effects may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well\-controlled.
  • 10\. Habituation to analgesic medications (i.e., routine use of oral analgesics 5 or more times per week).

Outcomes

Primary Outcomes

Not specified

Similar Trials